Bearish
10
Bullish
32
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2023-03-23 | 2022-12 | 0 | N/A | N/A | N/A |
| 2022-12-01 | 2022-09 | -0.14 | N/A | N/A | N/A |
| 2022-08-17 | 2022-06 | -0.22 | N/A | N/A | N/A |
| 2022-05-17 | 2022-03 | -0.25 | N/A | N/A | N/A |
| 2022-03-10 | 2021-12 | -0.22 | N/A | N/A | N/A |
| 2021-11-04 | 2021-09 | -0.22 | N/A | N/A | N/A |
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-08-30 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2022-06-03 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2022-04-26 | Canaccord Genuity | Upgrade | Buy | |
| 2022-03-28 | Aegis Capital | Upgrade | Buy | |
| 2022-03-28 | HC Wainwright & Co. | Upgrade | Buy | |
| 2021-11-29 | HC Wainwright & Co. | Upgrade | Buy |
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-02-27 | LOUMAYE ERNEST | Director | 6.00M | Purchase |
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-12-30 | Sofinnova Investments, Inc. | 4.75M | 483.51K | 4.37% |
| 2022-12-30 | NEA Management Company, LLC | 4.59M | 466.91K | 4.22% |
| 2022-12-30 | Credit Suisse Ag/ | 1.75M | 178.21K | 1.61% |
| 2022-12-30 | Zurcher Kantonalbank (Zurich Cantonalbank) | 668.49K | 68.05K | 0.62% |
| 2022-12-30 | Pictet Asset Management SA | 363.77K | 37.03K | 0.33% |
| 2022-12-30 | Cutter & Co. Brokerage, Inc. | 201.20K | 20.48K | 0.19% |
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-11-29 | Fidelity NASDAQ Composite Index Fund | 82.23K | 8.37K | 0.08% |
-
ObSeva Announces Positive Pilot Study Results From Linzagolix In Adenomyosis
Obseva SA (NASDAQ: OBSV) announced the publication in the journal Fertility and Sterility of a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis. The study showed the patient treated with linzagolix saw alleviation of symptoms such as cessation of bleeding, improvement in pelvic pain, resolution of anemia and shrinkage of uterus at week 12.
The symptoms continued to improve with the subsequent 12 weeks of treatment, and the effect lingered at eight weeks following the treatment.
Pending confirmation of the results in additional patients, ObsEva said it may pursue additional studies to support supplemental labeling for the treatment of adenomyosis in reproductive-age women.
-
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility and Sterility of “Gonadotropin-releasing Hormone Antagonist (linzagolix): a New Therapy for Uterine Adenomyosis,” a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis.
-
-
-
-
-
Huge buys now. Stock barely went up
-
Don’t believe the bots telling you to hold. This things is manipulated and going down hard. Won’t be back for months of at all. Unless they decide to pump
-
Sucked all the gains out of my account
-
I’m out with a loss. Had to stop the bleeding
-
@John smith. Where did you read offering?
-
Stuck here at 4.55 till this turns around
if it goes all the way to 52 week low I’ll add more and hold. Hopefully good news in March -
Why so much after hours activity. More movements than open hrs. Anyone?
-
Market is booming today while this dog sleeps
